This phase I trial seeks to understand how safe and tolerable an immunotherapy drug (AMG 757) is in people with neuroendocrine prostate cancer.
This trial is treating patients with neuroendocrine prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
This is a non-randomised study with two phases. In Phase 1 (dose exploration) participants will receive AMG 757 administered intravenously with the aim of identifying the maximum tolerated (MTD) and/or recommended phase 2 dose (RP2D). In Phase 2 (dose expansion), participants will receive the recommended phase 2 dose (RP2D) of AMG 757 identified in Part 1 (administered intravenously).
Recruiting Hospitals Read More